TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tai Chi After Pulmonary Rehabilitation in Patients With COPD: A Randomized Trial
Brief Summary: The main purpose of this study is to determine the feasibility and effects of a 6-month tai chi exercise program as compared to a 6-month group walking program and standard care for patients with COPD that have recently completed a pulmonary rehabilitation program.


Options:
A: Arm Label: HappyAir Group; Type: EXPERIMENTAL; Interventions: Other: Pulmonary Care Web-Based App (HappyAir App) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pulmonary Care Web-Based App (HappyAir App); Assigned to Arm(s): HappyAir Group
B: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Tai Chi Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Chi | Arm Label: Group Walking Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Group Walking | Intervention Type: BEHAVIORAL; Name: Tai Chi; Assigned to Arm(s): Tai Chi Exercise | Intervention Type: BEHAVIORAL; Name: Group Walking; Assigned to Arm(s): Group Walking Exercise
C: Arm Label: MOBILE-A; Type: EXPERIMENTAL; Interventions: Behavioral: Coached exercise persistence intervention | Arm Label: MOBILE-B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Monitored exercise persistence intervention | Intervention Type: BEHAVIORAL; Name: Coached exercise persistence intervention; Assigned to Arm(s): MOBILE-A | Intervention Type: BEHAVIORAL; Name: Self-Monitored exercise persistence intervention; Assigned to Arm(s): MOBILE-B
D: Arm Label: Device: KAIA COPD-App (Medical Mobile Application).; Type: EXPERIMENTAL; Interventions: Device: Kaia COPD Application | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DEVICE; Name: Kaia COPD Application; Assigned to Arm(s): Device: KAIA COPD-App (Medical Mobile Application). | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)
Brief Summary: The purpose of this study is to assess the efficacy and dose response of intranasal esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with placebo in improving depressive symptoms in participants with treatment-resistant depression (TRD).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): N/A
C: Arm Label: Esketamine 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Esketamine 14 mg, Drug: Esketamine 56 mg, Drug: Placebo | Arm Label: Esketamine 28 mg; Type: EXPERIMENTAL; Interventions: Drug: Esketamine 28 mg, Drug: Esketamine 56 mg, Drug: Placebo | Arm Label: Esketamine 56 mg; Type: EXPERIMENTAL; Interventions: Drug: Esketamine 56 mg, Drug: Placebo | Arm Label: Esketamine 84 mg; Type: EXPERIMENTAL; Interventions: Drug: Esketamine 56 mg, Drug: Esketamine 84 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Esketamine 14 mg, Drug: Esketamine 28 mg, Drug: Esketamine 56 mg, Drug: Esketamine 84 mg, Drug: Placebo | Intervention Type: DRUG; Name: Esketamine 14 mg; Assigned to Arm(s): Esketamine 14 mg, Placebo | Intervention Type: DRUG; Name: Esketamine 28 mg; Assigned to Arm(s): Esketamine 28 mg, Placebo | Intervention Type: DRUG; Name: Esketamine 56 mg; Assigned to Arm(s): Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo | Intervention Type: DRUG; Name: Esketamine 84 mg; Assigned to Arm(s): Esketamine 84 mg, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo
D: Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Arm Label: Ketamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Midazolam

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry
Brief Summary: The purpose of this study is to compare the effectiveness of extended-release naltrexone (XR-NTX) vs. enhanced treatment-as-usual (TAU) among opioid dependent adults leaving NYC jails. In parallel, we propose to recruit a matched, quasi-experimental methadone cohort, which will result in a naturalistic comparison of XR-NTX vs. an established jail-based methadone treatment program standard-of-care. Our primary aim is to compare time-to-relapse among participants treated with XR-NTX vs. randomized TAU controls and time-to-relapse among XR-NTX arm vs. jail-based MTP participants, following release from jail. Secondary aims will compare related opioid treatment outcomes post-release across all arms.


Options:
A: Arm Label: Intramuscular naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vivitrol- Intramuscular naltrexone (depot-formulation) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vivitrol- Intramuscular naltrexone (depot-formulation); Assigned to Arm(s): Intramuscular naltrexone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Extended-Release Naltrexone (XR-NTX); Type: EXPERIMENTAL; Interventions: Drug: Extended-Release Naltrexone | Arm Label: Enhanced Treatment As Usual (ETAU); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Methadone Treatment Program (MTP); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Extended-Release Naltrexone; Assigned to Arm(s): Extended-Release Naltrexone (XR-NTX)
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Core; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Core | Arm Label: Enhanced; Type: EXPERIMENTAL; Interventions: Behavioral: Core, Behavioral: Enhanced | Intervention Type: BEHAVIORAL; Name: Core; Assigned to Arm(s): Core, Enhanced | Intervention Type: BEHAVIORAL; Name: Enhanced; Assigned to Arm(s): Enhanced
D: Arm Label: Extended-Release Naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Intervention Type: DRUG; Name: Extended-Release Naltrexone; Assigned to Arm(s): Extended-Release Naltrexone, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessing the Effectiveness of a Weight Watchers-based Lifestyle Intervention for the Primary Prevention of Type 2 Diabetes
Brief Summary: This study is a randomized pilot study to assess the applicability of the Weight Watchers model for lifestyle modification to the primary prevention of type 2 diabetes. The approach developed by Weight Watchers to achieve weight loss is based on similar nutritional principals and techniques used in the Diabetes Prevention Program (DPP) lifestyle intervention; monitoring food intake, exercising calorie control, setting modest weight loss goals and using physical activity.


Options:
A: Arm Label: Lifestyle; Type: EXPERIMENTAL; Interventions: Behavioral: Group-Based Lifestyle Intervention (Phases 1 and 2), Behavioral: Self-Directed Maintenance (Phase 3), Behavioral: Extended Group Maintenance (Phase 3) | Arm Label: Comparison; Type: OTHER; Interventions: Other: Individual Education Program (All Phases) | Intervention Type: BEHAVIORAL; Name: Group-Based Lifestyle Intervention (Phases 1 and 2); Assigned to Arm(s): Lifestyle | Intervention Type: OTHER; Name: Individual Education Program (All Phases); Assigned to Arm(s): Comparison | Intervention Type: BEHAVIORAL; Name: Self-Directed Maintenance (Phase 3); Assigned to Arm(s): Lifestyle | Intervention Type: BEHAVIORAL; Name: Extended Group Maintenance (Phase 3); Assigned to Arm(s): Lifestyle
B: Arm Label: Lifestyle coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Watchers | Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight Watchers, Behavioral: National Diabetes Education Program | Intervention Type: BEHAVIORAL; Name: Weight Watchers; Assigned to Arm(s): Lifestyle coaching, Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: National Diabetes Education Program; Assigned to Arm(s): Lifestyle counseling
C: Intervention Type: BEHAVIORAL; Name: A lifestyle educational program; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: weight management program; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Do Progressive Levels of Simulation Fidelity Enhance Colonoscopic Skill Acquisition and Transfer in Novice Endoscopic Trainees?
Brief Summary: It is hypothesized that a progressive simulated learning strategy will result in better global clinical performance (e.g., technical, communication) and transfer of endoscopic skill, as compared with a high-fidelity simulation strategy.


Options:
A: Arm Label: Progressive Group; Type: EXPERIMENTAL; Interventions: Behavioral: Progressive Group | Arm Label: High-Fidelity Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Progressive Group; Assigned to Arm(s): Progressive Group
B: Arm Label: STAC curriculum; Type: EXPERIMENTAL; Interventions: Other: STAC curriculum | Arm Label: Conventional Curriculum; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: STAC curriculum; Assigned to Arm(s): STAC curriculum
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: simulator training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: simulator training | Intervention Type: DEVICE; Name: simulator training; Assigned to Arm(s): 1, 2
D: Arm Label: Fecal occult blood testing; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Immunochemical fecal occult blood test | Arm Label: Colonoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Colonoscopy | Intervention Type: PROCEDURE; Name: Immunochemical fecal occult blood test; Assigned to Arm(s): Fecal occult blood testing | Intervention Type: PROCEDURE; Name: Colonoscopy; Assigned to Arm(s): Colonoscopy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The investigators propose to perform a clinical randomized trial to evaluate the effect of a frozen-thawed embryo transfer and a fresh embryo transfer on pregnancy and implantation rates; with the added benefit of a blastocyst biopsy and whole chromosome analysis by Next Generation Sequencing (NGS).


Options:
A: Arm Label: Freeze-all protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Freeze-all protocol | Arm Label: Fresh transfer protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh transfer protocol | Intervention Type: PROCEDURE; Name: Freeze-all protocol; Assigned to Arm(s): Freeze-all protocol | Intervention Type: PROCEDURE; Name: Fresh transfer protocol; Assigned to Arm(s): Fresh transfer protocol
B: Arm Label: Fresh transfer; Type: ACTIVE_COMPARATOR; Interventions: Procedure: fresh transfer | Arm Label: Deferred-frozen embryo transfer; Type: EXPERIMENTAL; Interventions: Procedure: Deferred-frozen embryo transfer | Intervention Type: PROCEDURE; Name: fresh transfer; Assigned to Arm(s): Fresh transfer | Intervention Type: PROCEDURE; Name: Deferred-frozen embryo transfer; Assigned to Arm(s): Deferred-frozen embryo transfer
C: Arm Label: Freeze all; Type: EXPERIMENTAL; Interventions: Procedure: Freeze all | Arm Label: Fresh embryo transfer; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Freeze all; Assigned to Arm(s): Freeze all
D: Arm Label: Frozen Embryo Transfer with PGD; Type: EXPERIMENTAL; Interventions: Other: PGD | Arm Label: Fresh Embryo Transfer with PGD; Type: EXPERIMENTAL; Interventions: Other: PGD | Intervention Type: OTHER; Name: PGD; Assigned to Arm(s): Fresh Embryo Transfer with PGD, Frozen Embryo Transfer with PGD

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The investigators propose to perform a clinical randomized trial to evaluate the effect of a frozen-thawed embryo transfer and a fresh embryo transfer on pregnancy and implantation rates; with the added benefit of a blastocyst biopsy and whole chromosome analysis by Next Generation Sequencing (NGS).


Options:
A: Arm Label: fresh embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: fresh embryo transfer | Arm Label: frozen-thawed embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: frozen-thawed embryo transfer | Intervention Type: OTHER; Name: fresh embryo transfer; Assigned to Arm(s): fresh embryo transfer group | Intervention Type: OTHER; Name: frozen-thawed embryo transfer; Assigned to Arm(s): frozen-thawed embryo transfer group
B: Arm Label: Blastocyst transfer in PTEC cycle; Type: EXPERIMENTAL; Interventions: Procedure: Embryo cryopreservation | Arm Label: Fresh blastocyst transfer.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh blastocyst transfer | Intervention Type: PROCEDURE; Name: Embryo cryopreservation; Assigned to Arm(s): Blastocyst transfer in PTEC cycle | Intervention Type: PROCEDURE; Name: Fresh blastocyst transfer; Assigned to Arm(s): Fresh blastocyst transfer.
C: Arm Label: Freeze-all protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Freeze-all protocol | Arm Label: Fresh transfer protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh transfer protocol | Intervention Type: PROCEDURE; Name: Freeze-all protocol; Assigned to Arm(s): Freeze-all protocol | Intervention Type: PROCEDURE; Name: Fresh transfer protocol; Assigned to Arm(s): Fresh transfer protocol
D: Arm Label: Frozen Embryo Transfer with PGD; Type: EXPERIMENTAL; Interventions: Other: PGD | Arm Label: Fresh Embryo Transfer with PGD; Type: EXPERIMENTAL; Interventions: Other: PGD | Intervention Type: OTHER; Name: PGD; Assigned to Arm(s): Fresh Embryo Transfer with PGD, Frozen Embryo Transfer with PGD

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Brief Summary: This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in metastatic breast cancer patients with gBRCA 1/2 mutations.


Options:
A: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Doxorubicin, Drug: Paclitaxel, Drug: Carboplatin, Drug: Veliparib | Arm Label: Arm C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Placebo, Drug: Doxorubicin, Drug: Paclitaxel | Arm Label: Arm B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Doxorubicin, Drug: Paclitaxel, Drug: Carboplatin, Drug: Placebo | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm C | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Veliparib; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm B, Arm C
B: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Physician's choice chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Physician's choice chemotherapy | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: Physician's choice chemotherapy; Assigned to Arm(s): Physician's choice chemotherapy
C: Arm Label: Arm G/C; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine/carboplatin | Arm Label: Arm G/C/I; Type: EXPERIMENTAL; Interventions: Drug: gemcitabine/carboplatin, Drug: iniparib | Intervention Type: DRUG; Name: gemcitabine/carboplatin; Assigned to Arm(s): Arm G/C, Arm G/C/I | Intervention Type: DRUG; Name: iniparib; Assigned to Arm(s): Arm G/C/I
D: Arm Label: Arm G/C; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine/carboplatin | Arm Label: Arm G/C/I; Type: EXPERIMENTAL; Interventions: Drug: gemcitabine/carboplatin, Drug: Iniparib | Intervention Type: DRUG; Name: gemcitabine/carboplatin; Assigned to Arm(s): Arm G/C, Arm G/C/I | Intervention Type: DRUG; Name: Iniparib; Assigned to Arm(s): Arm G/C/I

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
Brief Summary: The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).


Options:
A: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel
B: Arm Label: Pembrolizumab 2 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Pembrolizumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Docetaxel 75 mg/m^2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab 10 mg/kg, Pembrolizumab 2 mg/kg | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Docetaxel 75 mg/m^2
C: Arm Label: Dose Escalation; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736, Drug: Tremelimumab | Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736, Drug: Tremelimumab | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736, Drug: tremelimumab | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736, Drug: tremelimumab | Intervention Type: DRUG; Name: MEDI4736; Assigned to Arm(s): Arm A, Arm B, Arm C, Dose Escalation | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): Arm A, Dose Escalation | Intervention Type: DRUG; Name: tremelimumab; Assigned to Arm(s): Arm B, Arm C
D: Arm Label: Arm A: Nivolumab subjects; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Investigator's Choice Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Nivolumab, Drug: Gemcitabine, Drug: Cisplatin, Drug: Carboplatin, Drug: Paclitaxel, Drug: Pemetrexed | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab subjects, Arm B: Investigator's Choice Chemotherapy | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm B: Investigator's Choice Chemotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm B: Investigator's Choice Chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm B: Investigator's Choice Chemotherapy | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm B: Investigator's Choice Chemotherapy | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Arm B: Investigator's Choice Chemotherapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sleep and Pain Interventions in Fibromyalgia: Hyperalgesia and Central Sensitization
Brief Summary: This is a single-center, randomized controlled trial study design. Enrolled participants had comorbid fibromyalgia and chronic insomnia. Participants were randomized to a behavioral intervention for pain, a behavioral intervention for insomnia, or a waitlist control. The study intervention period lasted eight weeks. The objective of the study is to examine the impact of two behavioral treatments on sleep and pain and to better understand what causes chronic pain and chronic sleep disturbance.


Options:
A: Arm Label: ACT; Type: EXPERIMENTAL; Interventions: Behavioral: ACT | Arm Label: Physical activity; Type: EXPERIMENTAL; Interventions: Other: Physical activity | Arm Label: Experience based discussion group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ACT; Assigned to Arm(s): ACT | Intervention Type: OTHER; Name: Physical activity; Assigned to Arm(s): Physical activity
B: Arm Label: Pain Ed; Type: EXPERIMENTAL; Interventions: Behavioral: Pain Ed, Other: Usual Care | Arm Label: CBT for Pain; Type: EXPERIMENTAL; Interventions: Behavioral: CBT for Pain, Other: Usual Care | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Pain Ed; Assigned to Arm(s): Pain Ed | Intervention Type: BEHAVIORAL; Name: CBT for Pain; Assigned to Arm(s): CBT for Pain | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): CBT for Pain, Pain Ed, Usual Care
C: Arm Label: Lifestyles A; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyles A | Arm Label: Lifestyle B; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyles B | Arm Label: Lifestyles C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyles C | Intervention Type: BEHAVIORAL; Name: Lifestyles A; Assigned to Arm(s): Lifestyles A | Intervention Type: BEHAVIORAL; Name: Lifestyles B; Assigned to Arm(s): Lifestyle B | Intervention Type: BEHAVIORAL; Name: Lifestyles C; Assigned to Arm(s): Lifestyles C
D: Arm Label: CBT-I; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I) | Arm Label: CBT-P; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy for Pain (CBT-P) | Arm Label: Waitlist Control (WLC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy for Insomnia (CBT-I); Assigned to Arm(s): CBT-I | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy for Pain (CBT-P); Assigned to Arm(s): CBT-P

Answer: D